Nat West Group PLC Vertex Pharmaceuticals Inc Transaction History

Nat West Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$407.69 - $446.08 $82,761 - $90,554	-203 Reduced 2.94%	6,691 $2.8 Million
Q4 2023 Jan 12, 2024	BUY	$343.0 - $410.68 $366,324 - $438,606	1,068 Added 18.33%	6,894 $2.81 Million
Q3 2023 Oct 12, 2023	BUY	$338.18 - $362.46 $42,948 - $46,032	127 Added 2.23%	5,826 $2.03 Million
Q2 2023 Jul 25, 2023	BUY	$314.42 - $351.91 $4,401 - $4,926	14 Added 0.25%	5,699 $2.01 Million
Q1 2023 Apr 24, 2023	SELL	$283.23 - $323.1 $3.86 Million - $4.41 Million	-13,639 Reduced 70.58%	5,685 $1.79 Million
Q4 2022 Jan 27, 2023	BUY	$285.76 - $321.48 $116,018 - $130,520	406 Added 2.15%	19,324 $0
Q3 2022 Oct 31, 2022	BUY	$273.83 - $305.53 $5.18 Million - $5.78 Million	18,918 New	18,918 $5.48 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Nat West Group PLC, based on Form 13F filings with the SEC.

Stay updated on Nat West Group PLC with notifications on news.